LOS ANGELES, June 18, 2024 /PRNewswire/ -- Partillion Bioscience Corporation ('Partillion'), a life science tools company, announced a new publication led by UCLA Professor Dino Di Carlo, revealing new insights into the therapeutic potential of extracellular vesicles (EVs). Using Partillion's Nanovial technology, which enables functional screening of thousands of individual cells, the study identified and isolated high EV-secreting stem cells and used them as a therapeutic in mice, demonstrating improved tissue regeneration post-cardiac injury.

洛杉矶，2024年6月18日/PRNewswire/--生命科学工具公司Partillion Bioscience Corporation（“Partillion”）宣布了一份由加州大学洛杉矶分校教授Dino Di Carlo领导的新出版物，揭示了对细胞外囊泡（EVs）治疗潜力的新见解。使用Partillion的纳米瓶技术，可以对数千个单个细胞进行功能筛选，该研究鉴定并分离出高EV分泌干细胞，并将其用作小鼠的治疗药物，证明心脏损伤后组织再生得到改善。

These findings highlight the therapeutic importance of EV secretion in regenerative cell therapies and suggest that selecting cells based on EV secretion could enhance therapeutic efficacy..

这些发现突出了EV分泌在再生细胞疗法中的治疗重要性，并表明基于EV分泌选择细胞可以提高治疗效果。。

Extracellular vesicles, lipid membrane-encapsulated particles secreted by cells, play crucial roles in intercellular communication and disease progression. They are thought to act as therapeutic mediators by recruiting cells with regenerative and anti-inflammatory functions. The heterogeneity of EV secretion among individual stem cells presents a challenge for developing robust therapeutics with consistent outcomes.

细胞外囊泡是细胞分泌的脂质膜包裹颗粒，在细胞间通讯和疾病进展中起着至关重要的作用。它们被认为通过募集具有再生和抗炎功能的细胞来充当治疗介质。。

Traditional methods, which study EV-secreting cells in bulk, often mask this heterogeneity and typically destroy the cells, making it difficult to optimize EV therapeutics..

。。

In the article 'Optimizing cell therapy by sorting cells with high extracellular vesicle secretion' published in Nature Communications, the Di Carlo lab used Partillion's Nanovial technology to categorize and separate mesenchymal stem cells (MSCs) by their secretion level of EVs.

。

'Up until now, no technology has been developed to analyze and sort single cells based on EV secretion levels,' said Professor Dino Di Carlo, senior author of the study. 'Nanovials allowed us to isolate high EV-secreting cells and keep them alive so we could treat a heart injury in a mouse similar to a heart attack in humans.

该研究的资深作者迪诺·迪卡罗（DinoDiCarlo）教授说，到目前为止，还没有开发出根据EV分泌水平对单细胞进行分析和分类的技术纳米小瓶使我们能够分离出高EV分泌细胞并使其存活，因此我们可以治疗类似于人类心脏病发作的小鼠心脏损伤。

Researchers can apply these methods to identify novel surface markers associated with high EV secretion to more easily select large quantities of the optimal cells for a human therapeutic. Alternatively, therapeutic targets can be identified that modulate EV secretion in vivo, enabling drug discovery, ultimately improving patient outcomes across many therapeutic modalities.'.

研究人员可以应用这些方法来鉴定与高EV分泌相关的新型表面标志物，以更容易地选择大量最佳细胞用于人类治疗。或者，可以确定调节体内EV分泌的治疗靶点，从而实现药物发现，最终改善许多治疗方式的患者预后。”。

Partillion's EZM Nanovial products are ideally suited for EV-based research. The matrix coating incorporated into the Nanovial cavities enables the isolation and growth of epithelial and mesenchymal cells often used for EV production. Antibodies against tetraspanins or other membrane-presented proteins on EVs can be used to isolate specific sub-populations of secreted EVs..

Partillion的EZM纳米瓶产品非常适合基于电动汽车的研究。掺入纳米小瓶腔中的基质涂层能够分离和生长通常用于EV生产的上皮细胞和间充质细胞。电动汽车上针对四跨膜蛋白或其他膜呈递蛋白的抗体可用于分离分泌型电动汽车的特定亚群。。

Joe de Rutte, CEO and Co-founder of Partillion Bioscience, commented, 'At Partillion, we are dedicated to building innovative tools that empower researchers to push the boundaries of science. It is incredibly exciting to imagine how these advancements in EV-based cell therapeutics, one of the most cutting-edge approaches to therapeutics, can translate into meaningful applications for human health.

。想象一下，基于EV的细胞疗法（最前沿的治疗方法之一）的这些进步如何转化为对人类健康有意义的应用，这是令人难以置信的兴奋。

Moving forward, we remain committed to continuously improving our products to facilitate this type of innovative research, ensuring that scientists have the tools they need to unlock new therapeutic potentials.'.

展望未来，我们仍然致力于不断改进我们的产品，以促进这类创新研究，确保科学家拥有释放新治疗潜力所需的工具。”。

About PartillionPartillion Bioscience is a venture-backed life science company developing a next generation single-cell analysis platform. Partillion's award winning Nanovial technology enables customers to accelerate therapeutic development to address the most difficult diseases and provide advanced scientific insights.

关于Partillion Partillion Bioscience是一家风险投资支持的生命科学公司，开发下一代单细胞分析平台。Partillion屡获殊荣的纳米瓶技术使客户能够加速治疗开发，以解决最困难的疾病，并提供先进的科学见解。

The reagent-based platform, with products available at www.partillion.com, unlocks the ability to screen hundreds of thousands to millions of individual cells based on critical yet difficult to probe functional information all while using easy to access lab equipment – solving a major pain point in the industry.

该基于试剂的平台的产品可在www.partillion.com上找到，它可以在使用易于访问的实验室设备的同时，根据关键但难以探测的功能信息筛选数十万至数百万个单个细胞，从而解决了该行业的一个主要痛点。

The technology underpinning Partillion's products was developed in Dino Di Carlo's lab (UCLA) and has been featured in notable journals such as Nature Communications, Nature Nanotechnology, Proceedings of the National Academy of Sciences of the USA, Science Advances, and ACS Nano and received industry accolades, winning the 2020 SLAS Innovation Award and 2022 SLAS New Product Award..

。。

SOURCE Partillion Bioscience

来源：Partillion Bioscience